More sensitive hepatitis C virus RNA detection: What for?

Journal of Hepatology

Volumn 52, Issue 6, 2010, Pages 783-785

  Pawlotsky, Jean Michel ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ACCURACY; CLINICAL TRIAL; DRUG RESPONSE; EDITORIAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VIRUS GENOME;

EID: 77952542305     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.02.007     Document Type: Editorial

References (26)

1. Pawlotsky J.M. Measuring hepatitis C viremia in clinical samples: can we trust the assays?. Hepatology 26 (1997) 1-4
2. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C, June 10-12, 2002. Hepatology 2002;36:S3-20.
3. Davis G.L., Wong J.B., McHutchison J.G., Manns M.P., Harvey J., and Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38 (2003) 645-652
4. Ferenci P., Fried M.W., Shiffman M.L., Smith C.I., Marinos G., Goncales Jr. F.L., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43 (2005) 425-433
5. Zeuzem S., Buti M., Ferenci P., Sperl J., Horsmans Y., Cianciara J., et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44 (2006) 97-103
6. Moreno C., Deltenre P., Pawlotsky J.M., Henrion J., Adler M., and Mathurin P. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol 52 (2010) 25-31
7. Berg T., von Wagner M., Nasser S., Sarrazin C., Heintges T., Gerlach T., et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130 (2006) 1086-1097
8. Pearlman B.L., Ehleben C., and Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 46 (2007) 1688-1694
9. Mangia A., Santoro R., Minerva N., Ricci G.L., Carretta V., Persico M., et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 352 (2005) 2609-2617
10. Shiffman M.L., Suter F., Bacon B.R., Nelson D., Harley H., Sola R., et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357 (2007) 124-134
11. Lagging M., Langeland N., Pedersen C., Farkkila M., Buhl M.R., Morch K., et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 47 (2008) 1837-1845
12. Pawlotsky J.M. Molecular diagnosis of viral hepatitis. Gastroenterology 122 (2002) 1554-1568
13. Chevaliez S., and Pawlotsky J.M. Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. Best Pract Res Clin Gastroenterol 22 (2008) 1031-1048
14. Chevaliez S., Bouvier-Alias M., Brillet R., and Pawlotsky J.M. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 46 (2007) 22-31
15. Chevaliez S., Bouvier-Alias M., Castera L., and Pawlotsky J.M. The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples. Hepatology 49 (2009) 1397-1398
16. RT for hepatitis C virus RNA quantification. J Clin Microbiol 47 (2009) 1726-1732
17. Vermehren J., Kau A., Gartner B.C., Gobel R., Zeuzem S., and Sarrazin C. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol 46 (2008) 3880-3891
18. Sarrazin C., Shiffman M.L., Hadziyannis S.J., Lin A., Colucci G., Ishida H., et al. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol 52 (2010) 832-838
19. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
20. Reesink H.W., Zeuzem S., Weegink C.J., Forestier N., van Vliet A., de Rooij J., et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131 (2006) 997-1002
21. Sarrazin C., Rouzier R., Wagner F., Forestier N., Larrey D., Gupta S.K., et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132 (2007) 1270-1278
22. Forestier N., Reesink H.W., Weegink C.J., McNair L., Kieffer T.L., Chu H.M., et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46 (2007) 640-648
23. Hezode C., Forestier N., Dusheiko G., Ferenci P., Pol S., Goeser T., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360 (2009) 1839-1850
24. McHutchison J.G., Everson G.T., Gordon S.C., Jacobson I.M., Sulkowski M., Kauffman R., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360 (2009) 1827-1838
25. Kwo P., Lawitz E., McCone J., Schiff E., Vierling J., Pound D., et al. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus PegIntron (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis C. J Hepatol 50 (2009) S4
26. Marcellin P., Forns X., Goeser T., Ferenci P., Nevens F., Carosi G., et al. Virological analysis of patients receiving telaprevir administered q8h or q12h with peginterferon alfa-2a or alfa-2b, ribavirin in treatment-naive patients with genotype 1 hepatitis C: study C208. Hepatology 50 (2009) 395A